Eli Lilly and Company

12/11/2024 | Press release | Distributed by Public on 12/11/2024 07:15

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2-[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.